This web page was created programmatically, to learn the article in its unique location you possibly can go to the hyperlink bellow: https://www.medrxiv.org/content/10.64898/2026.07.12.26357861v1and if you wish to take away this text from our web site please contact us [ad_1] AbstractBackground: Multidomain way of life interventions concentrating on a number of threat elements have been proposed to scale back cognitive impairment and dementia threat. However, combined findings hamper their utility. More proof is required to optimise approaches in several settings. The rising variety of scientific trials being performed warrants an up-to-date synthesis. Methods: We performed a scientific overview and meta-analysis of randomised managed trials (RCTs) testing multidomain interventions (three or extra elements) on cognition or dementia incidence. Maximum-likelihood random-effect fashions have been utilized. Sensitivity analyses have been performed to discover supply of heterogeneity Meta-regression analyses have been performed, together with by intervention period and depth. Risk of bias on cognition was assessed utilizing the revised Cochrane risk-of-bias device for RCTs (RoB-2) Heterogeneity was estimated utilizing Chi2 take a look at, I2 statistics, and 95% prediction intervals GRADE was used for proof certainty evaluation. Results: After screening 4759 and full-text studying 128 publications, 43 RCTs have been eligible and 41 included within the meta-analysis (N=23209). Risk of bias was typically low, with most issues in older research Small however statistically important intervention advantages have been discovered for international cognition (composite rating of validated neuropsychological exams; SMD=0,28; 95% CI: 0,10 to 0,45), and many of the different cognitive measures. High heterogeneity was noticed for international cognition composite scores and may very well be solely partially defined by three smaller RCTs. Intervention effect-size was considerably related to shorter period (P-value=0,009) and better noticed depth (P-value=0,008). Interpretation: Multidomain interventions have small however constant useful results on cognitive measures, suggesting the potential to scale back cognitive impairment and dementia threat. High heterogeneity throughout RCTs can hinder knowledge pooling. More proof on longer-term impact is required. Future analysis ought to prioritise harmonisation of methodologies and reporting, long-term prolonged follow-up knowledge, clinically related dementia-risk surrogate outcomes, and proof from extra numerous cultural, geographical, and socio-economic contexts.Competing Interest StatementThe authors have declared no competing curiosity.Clinical Protocolshttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251018238Author DeclarationsI affirm all related moral pointers have been adopted, and any crucial IRB and/or ethics committee approvals have been obtained.YesThe particulars of the IRB/oversight physique that offered approval or exemption for the analysis described are given beneath:Data used are from RCTs for which data is brazenly accessible and might be positioned at Medline by way of OVID; EMBASE by way of Elsevier; The Cochrane Library by way of Wiley; ClinicalTrials.gov; and the WHO International Clinical Trials Registry PlatformI affirm that every one crucial affected person/participant consent has been obtained and the suitable institutional varieties have been archived, and that any affected person/participant/pattern identifiers included weren't identified to anybody (e.g., hospital employees, sufferers or individuals themselves) exterior the analysis group so can't be used to establish people.YesI perceive that every one scientific trials and another potential interventional research have to be registered with an ICMJE-approved registry, similar to ClinicalTrials.gov. I affirm that any such research reported within the manuscript has been registered and the trial registration ID is offered (notice: if posting a potential research registered retrospectively, please present an announcement within the trial ID discipline explaining why the research was not registered prematurely).Yes I've adopted all acceptable analysis reporting pointers, similar to any related EQUATOR Network analysis reporting guidelines(s) and different pertinent materials, if relevant.YesData Availabilitymaterials from the meta-analysis we're open to share consists of template knowledge assortment varieties; knowledge extracted from included research; knowledge used for all analyses; analytic code; another supplies used within the overview, could also be offered upon cheap request to the corresponding writer and upon approval of all authors.Funder Information DeclaredInnovative Health Initiative, https://ror.org/04afqts81, grant 101132933Joint Program Neurodegenerative Disease Research, 357810Research Council of Finland, https://ror.org/05k73zm37, 360824, 362706 [ad_2] This web page was created programmatically, to learn the article in its unique location you possibly can go to the hyperlink bellow: https://www.medrxiv.org/content/10.64898/2026.07.12.26357861v1and if you wish to take away this text from our web site please contact us